Risperidone is highly effective in children with breath holding spells and reflex anoxic seizures: A proof-of-concept study

Sandhya AP¹, Ramesh Konanki¹, Vivek Jain², Lokesh Lingappa¹ Apoorva Gupta¹
¹Rainbow Children's Hospital, Hyderabad, India, ²Neo Clinic Children's Hospital, Jaipur, India



With Pre-Iron Therapy (n=12)

reducti

RIS

Value

Introduction

 Breath holding spells (BHS) with reflex anoxic seizures (RAS) in children are a major source of stress to parents

Methods


· Descriptive analytical study

Results

- 24 children enrolled:13 boys
- Mean age at onset: 8.9 months (0.5-18 m)
- Mean age at onset: 8.9 months (0.3-16 m)
 Mean age at presentation: 16.2 months (3-36)
- 17 children presented with complaint of BHS (70.8%), 7 children (29.2%) presented with
- (70.8%), 7 children (29.2%) presented with paroxysmal events misdiagnosed as epilepsy
 19 children (79.2%) RAS with BHS
- All 24 children (100%) had microcytic,

Piracetam

- hypochromic anaemia
- At presentation, 8 children (29.2%) on Iron supplements, four (16.7%) on Iron and
- Mean and median total daily dose of Risperidone was 0.32 mg and 0.25 mg (dose/kg/day: 0.032 and 0.030)



	Before RIS	After RIS	% reduction	p Value
Mean BHS frequency per month (±2SD)	34.2 (55.02)	0.74 (1.26)	97.8	0.004
Mean duration of BHS in minutes (±2SD)	1.2 (0.85)	0.30 (0.52)	75	0.0001

Effect of Risperidone on BHS (n=24)

RIS ction on Mean BHS 21.85 0.66 46.5 0.81 98.2 0.023 frequency (41.69 (1.23)(1.3 per month (65.2)(±2SD) 5) 1.34 0.30 Mean 1.06 0.30 71.6 0.005 (0.74)duration of (0.96)(0.61)(0.4)BHS in 4) minutes (±2SD) RIS causes significant reduction in severity of BHS

Valu

re

Without Pre-Iron therapy (n=12)

redu

After

RIS

Before

- RIS causes significant reduction in severity of BHS
 RIS resulted in significantly reduced severity of BHS irrespective of preceding Iron therapy; Even Iron non responders had significant reduction in BHS
- No major or minor adverse events noted in any subject
 - Conclusions

 Risperidone is safe and highly effective for BHS and RAS in children, including Iron non-responders

Wilcoxon signed rank test

Contact author: drkonankiramesh@rainbowhospitals.in